文献速递呼吸道感染呼吸危重症与机械通气

伊维菌素与住院COVID-19患者较低死亡率相关

Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.
PubMed 文献 · Chest · 2020-10-13

单因素分析显示伊维菌素组院内全因死亡率较低(15.0% vs 25.2%),多因素调整及倾向评分匹配后差异仍显著,但为回顾性研究,需随机对照试验证实。

要点

  • 伊维菌素组院内全因死亡率低于未用药组(15.0% vs 25.2%)。
  • 重度肺部受累患者中伊维菌素组死亡率亦较低(38.8% vs 80.7%)。
  • 结果为回顾性观察,作者明确指出需随机对照试验确认。

核心结论

  • 住院COVID-19患者中,伊维菌素治疗与较低的院内全因死亡率相关,尤其在重度肺部受累患者中。
  • 作者指出该关联需随机对照试验证实。

研究设计与样本

  • 回顾性队列研究,连续纳入佛罗里达州四家Broward Health医院2020年3月15日至5月11日确诊COVID-19的住院患者。

主要发现

  • 单因素分析:伊维菌素组死亡率15.0% vs 25.2%(OR 0.52,95%CI 0.29-0.96,P=.03)。
  • 重度肺部受累患者死亡率38.8% vs 80.7%(OR 0.15,95%CI 0.05-0.47,P=.001)。
  • 拔管率(36.1% vs 15.4%;OR 3.11,95%CI 0.88-11.00,P=.07)与住院时长无显著差异。
  • 多因素调整后死亡率差异仍显著(OR 0.27,95%CI 0.09-0.80,P=.03)。
  • 倾向评分匹配队列中死亡率13.3% vs 24.5%(OR 0.47,95%CI 0.22-0.99,P<.05),绝对风险降低11.2%(95%CI 0.38%-22.1%),NNT 8.9(95%CI 4.5-263)。

关键数值与推荐

  • 重度肺部受累定义:研究开始时需要Fio2≥50%、无创通气或有创通气。
  • 两组多数患者同时接受羟氯喹、阿奇霉素或两者联用。

临床怎么用

  • 结果支持伊维菌素与住院COVID-19患者较低死亡率相关,但属回顾性证据,不能据此确立适应证。
  • 临床决策应等待随机对照试验结果,不宜仅凭本研究的关联性结论常规使用伊维菌素。

局限性

  • 为回顾性 chart 复习,非随机对照设计,治疗由主治医师决定,存在选择偏倚可能。
  • 作者明确指出需随机对照试验确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ivermectin was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro, which has led to off-label use, but clinical efficacy has not been described previously. RESEARCH QUESTION: Does ivermectin benefit hospitalized coronavirus disease 2019 (COVID-19) patients? STUDY DESIGN AND METHODS: Charts of consecutive patients hospitalized at four Broward Health hospitals in Florida with confirmed COVID-19 between March 15 and May 11, 2020, treated with or without ivermectin were reviewed. Hospital ivermectin dosing guidelines were provided, but treatment decisions were at the treating physician's discretion. The primary outcome was all-cause in-hospital mortality. Secondary outcomes included mortality in patients with severe pulmonary involvement, extubation rates for mechanically ventilated patients, and length of stay. Severe pulmonary involvement was defined as need for Fio2 ≥ 50%, noninvasive ventilation, or invasive ventilation at study entry. Logistic regression and propensity score matching were used to adjust for confounders. RESULTS: Two hundred eighty patients, 173 treated with ivermectin and 107 without ivermectin, were reviewed. Most patients in both groups also received hydroxychloroquine, azithromycin, or both. Univariate analysis showed lower mortality in the ivermectin group (15.0% vs 25.2%; OR, 0.52; 95% CI, 0.29-0.96; P = .03). Mortality also was lower among ivermectin-treated patients with severe pulmonary involvement (38.8% vs 80.7%; OR, 0.15; 95% CI, 0.05-0.47; P = .001). No significant differences were found in extubation rates (36.1% vs 15.4%; OR, 3.11; 95% CI, 0.88-11.00; P = .07) or length of stay. After multivariate adjustment for confounders and mortality risks, the mortality difference remained significant (OR, 0.27; 95% CI, 0.09-0.80; P = .03). One hundred ninety-six patients were included in the propensity-matched cohort. Mortality was significantly lower in the ivermectin group (13.3% vs 24.5%; OR, 0.47; 95% CI, 0.22-0.99; P < .05), an 11.2% (95% CI, 0.38%-22.1%) absolute risk reduction, with a number needed to treat of 8.9 (95% CI, 4.5-263). INTERPRETATION: Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement. Randomized controlled trials are needed to confirm these findings.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Rajter JC, Sherman MS, Fatteh N, et al. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2020. PMID: 33065103. doi:10.1016/j.chest.2020.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。